Wen Lin

1.3k total citations
26 papers, 566 citations indexed

About

Wen Lin is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wen Lin has authored 26 papers receiving a total of 566 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wen Lin's work include Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Research Studies (4 papers). Wen Lin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Research Studies (4 papers). Wen Lin collaborates with scholars based in China, United States and Spain. Wen Lin's co-authors include David R. Spigel, Craig H. Reynolds, George R. Blumenschein, Edward B. Garon, Jin Zhu, Paul J. Thurmes, Jason C. Chandler, Alexander I. Spira, Robert M. Jotte and David Waterhouse and has published in prestigious journals such as Journal of Clinical Oncology, Applied Physics Letters and Analytical Chemistry.

In The Last Decade

Wen Lin

25 papers receiving 561 citations

Peers

Countries citing papers authored by Wen Lin

Since Specialization

Citations

This map shows the geographic impact of Wen Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen Lin more than expected).

Fields of papers citing papers by Wen Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen Lin. The network helps show where Wen Lin may publish in the future.

Co-authorship network of co-authors of Wen Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Wen Lin. A scholar is included among the top collaborators of Wen Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wen Lin. Wen Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Plasma extracellular vesicle proteomics identifies FN1/F13A1–TGF-β pathway as the major signaling pathway associated with persistent atrial fibrillation 2025 ·Journal of Pharmaceutical and Biomedical Analysis ·Lili Zhang, Wen Lin, (unknown), (unknown), (unknown), (unknown), Qin Yang, Guo‐Wei He	0
2	Innovative BIM technology application in the construction management of highway 2024 ·Scientific Reports ·Dong Zhou, (unknown), Xueqin Li, (unknown), Wen Lin	14
3	Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors 2024 ·Journal for ImmunoTherapy of Cancer ·Matthew H. Taylor, Aung Naing, John D. Powderly, Paul Woodard, (unknown), Wen Lin, (unknown), Nathan O. Siemers, Hong Xiang, (unknown), Kyu Hong, (unknown), Tao Huang, Ying Zhu, Xuebin Liao, Xiao Min Schebye, Manish Patel	4
4	Suppressing laves phase and overcoming magnetic properties tradeoff in nanostructured (Ce,La,Y)–Fe–B alloys via Ge substitution 2023 ·Applied Physics Letters ·(unknown), Wei Li, Wen Lin, Chengyuan Xu, Xuefeng Liao, (unknown), Yu Pan, Xiaolian Liu, Song Fu, Lizhong Zhao, Hongya Yu, Xichun Zhong, Xuefeng Zhang, Liu Hon	4
5	A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer 2023 ·BMC Cancer ·Ernest Nadal, Mansoor N. Saleh, Santiago Ponce Aix, María Ochoa-de-Olza, Sandip Pravin Patel, Scott Antonia, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Shawn T. Estrem, Jiangang Liu, Emin Avşar, Wen Lin, Karim A. Benhadji, Leena Gandhi, Susan C. Guba, Inmaculada Alés Díaz	36
6	Serum Lipidomic Fingerprints Encode Early Diagnosis and Staging of Lung Cancer on a Novel PbS/Au-Layered Substrate 2023 ·ACS Applied Materials & Interfaces ·(unknown), (unknown), Yang Su, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Wenhua Gao, Yuping Chen, Wen Lin, Wen‐Xiu Ni, Yan Lin, Kwan‐Ming Ng	4
7	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials 2022 ·Journal for ImmunoTherapy of Cancer ·Yoon‐Koo Kang, Martin Reck, Paul Nghiem, Feng Yan, Gregory E. Plautz, Hye Ryun Kim, Taofeek K. Owonikoko, Narikazu Boku, Li‐Tzong Chen, Ming Lei, Han Chang, Wen Lin, Amit Roy, Akintunde Bello, Jennifer Sheng	10
8	747 A phase 1 trial of IO-202, an antagonist antibody targeting myeloid checkpoint LILRB4 (ILT3), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·Aung Naing, (unknown), Meredith Pelster, Alexander I. Spira, Reva Schneider, Paul Woodard, (unknown), Elizabeth A. Wieland, (unknown), Kyu Hong, Tao Huang, Xuebin Liao, Hong Xiang, Heinz‐Josef Lenz, Wen Lin	4
9	Combining MALDI-MS with machine learning for metabolomic characterization of lung cancer patient sera 2021 ·Analytical Methods ·(unknown), (unknown), Wei Huang, Yang Su, Siyu Chen, (unknown), (unknown), Wenhua Gao, (unknown), Yuping Chen, (unknown), Wen Lin, Xiaolong Wei, Wen‐Xiu Ni, Yan Lin, Dazhi Jiang, Yu-Hong Cheng, Chi‐Ming Che, Kwan‐Ming Ng	7
10	Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641) 2020 ·Clinical Cancer Research ·Xinghao Ai, Jiuwei Cui, Jiexia Zhang, Rongrong Chen, Wen Lin, Congying Xie, Anwen Liu, Junping Zhang, (unknown), Xiaohua Hu, Xiaohua Hu, Qiong Zhao, Chuangzhou Rao, (unknown), (unknown), Pansong Li, Lianpeng Chang, Xin Yi, Shun Lu	31
11	Clonal dominance of EGFR and efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC. 2020 ·Journal of Clinical Oncology ·Xinghao Ai, Rongrong Chen, Jiuwei Cui, Jiexia Zhang, Wen Lin, Congying Xie, Xiaohua Hu, Junping Zhang, Xiao‐Dong Jiao, Chuangzhou Rao, (unknown), Lianpeng Chang, Xuefeng Xia, Xin Yi, Shun Lü	1
12	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort 2019 ·Journal of Thoracic Oncology ·Neal Ready, Patrick A. Ott, Matthew D. Hellmann, Jon Zugazagoitia, Christine L. Hann, Filippo de Braud, Scott Antonia, Paolo A. Ascierto, Víctor Moreno, Akin Atmaca, Stefania Salvagni, Matthew H. Taylor, Asim Amin, D. Ross Camidge, Leora Horn, Emiliano Calvo, Ang Li, Wen Lin, Margaret K. Callahan, David R. Spigel	218
13	Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032 2018 ·Annals of Oncology ·Jonathan E. Rosenberg, Padmanee Sharma, Filippo de Braud, Umberto Basso, Emiliano Calvo, Petri Bono, Michael A. Morse, Paolo A. Ascierto, José A. López-Martín, Peter Brossart, Kristoffer Staal Rohrberg, Noemı́ Reguart, Wen Lin, S. Meadows–Shropshire, Abdel Saci, Margaret K. Callahan, Arlene O. Siefker‐Radtke	10
14	Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370) 2018 ·Journal of Thoracic Oncology ·David R. Spigel, Craig H. Reynolds, David Waterhouse, Edward B. Garon, Jason C. Chandler, Sunil Babu, Paul J. Thurmes, Alexander I. Spira, Robert M. Jotte, Jin Zhu, Wen Lin, George R. Blumenschein	178
15	Different definitions of esophagus influence esophageal toxicity prediction for esophageal cancer patients administered simultaneous integrated boost versus standard-dose radiation therapy 2017 ·Scientific Reports ·Bao-Tian Huang, (unknown), (unknown), Wen Lin, (unknown), (unknown), (unknown), Jianzhou Chen, Derui Li, Chuangzhen Chen	2
16	PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC 2016 ·Journal of Thoracic Oncology ·George R. Blumenschein, Jason C. Chandler, Edward B. Garon, David Waterhouse, Jonathan W. Goldman, Vijay Gunuganti, Ralph V. Boccia, David R. Spigel, John A. Glaspy, Donald A. Berry, Beata Korytowsky, Jin Zhu, Wen Lin, Kelly L. Bennett, Craig H. Reynolds	4
17	Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma 2013 ·Medical Oncology ·(unknown), Wen Lin, (unknown), (unknown), (unknown), Yingcheng Lin	9
18	Relationship between non-Hodgkin' s lymphoma and hepatitis B virus infection 2012 ·Wen Lin, Yingcheng Lin, (unknown), (unknown), (unknown)	1
19	Zoledronic acid inhibits human nasopharyngeal carcinoma cell proliferation by activating mitochondrial apoptotic pathway 2012 ·Medical Oncology ·(unknown), Yingcheng Lin, (unknown), Wen Lin, (unknown), (unknown), (unknown)	10
20	Effect of neoadjuvant chemotherapy combined with concurrent radiotherapy and chemotherapy for advanced nasopha ryngeal carcinoma in early-to-middle adulthood 2008 ·Zhonghua zhongliu fangzhi zazhi ·Wen Lin	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact